Last reviewed · How we verify
Seasonal Trivalent Influenza Vaccine
Seasonal Trivalent Influenza Vaccine is a Biologic drug developed by University of Maryland, Baltimore. It is currently FDA-approved.
At a glance
| Generic name | Seasonal Trivalent Influenza Vaccine |
|---|---|
| Sponsor | University of Maryland, Baltimore |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (PHASE3)
- A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision (EARLY_PHASE1)
- Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived) (PHASE3)
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age (PHASE3)
- Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Seasonal Trivalent Influenza Vaccine CI brief — competitive landscape report
- Seasonal Trivalent Influenza Vaccine updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI
Frequently asked questions about Seasonal Trivalent Influenza Vaccine
What is Seasonal Trivalent Influenza Vaccine?
Seasonal Trivalent Influenza Vaccine is a Biologic drug developed by University of Maryland, Baltimore.
Who makes Seasonal Trivalent Influenza Vaccine?
Seasonal Trivalent Influenza Vaccine is developed and marketed by University of Maryland, Baltimore (see full University of Maryland, Baltimore pipeline at /company/university-of-maryland-baltimore).
What development phase is Seasonal Trivalent Influenza Vaccine in?
Seasonal Trivalent Influenza Vaccine is FDA-approved (marketed).